Comparator QIV

BIOLOGICAL3 trials

Sponsors

Seqirus

Conditions

HumanInfluenzaInfluenza, HumanVirus Diseases

Phase 3

A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 5 Through 17 Years of Age

CompletedNCT02545543

SeqirusInfluenza, Human

Start: 2015-09-30End: 2016-06-30Updated: 2018-05-23

Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects

CompletedNCT04074928

SeqirusHuman, Influenza, Virus Diseases

Start: 2019-09-06End: 2020-09-03Updated: 2022-01-12

A Clinical Study to Evaluate the Immunogenicity and Safety of an Adjuvanted Quadrivalent Influenza Vaccine Compared With a Licensed Quadrivalent Vaccine in Adults 50 to 64 Years of Age

CompletedNCT05044195

SeqirusInfluenza, Human

Start: 2021-09-30End: 2022-09-09Updated: 2023-09-28

Related Papers

Immunogenicity and safety of a quadrivalent inactivated influenza virus vaccine compared with a comparator quadrivalent inactivated influenza vaccine in a pediatric population: A phase 3, randomized noninferiority study

Vaccine2017-04-059 citations